Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26?
The rapid spread of SARS-CoV-2, a novel coronavirus that emerged in late 2019, and the resulting COVID-19 pandemic, has been labeled as a public health emergency of international concern by the World Health Organization. Individuals with diabetes mellitus are at high risk for severe manifestations o...
Main Authors: | M. Maia Pinheiro, J. Monteiro Pinheiro, F. Moura Maia Pinheiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Verduci Editore
2020-04-01
|
Series: | CellR4 |
Subjects: | |
Online Access: | https://www.cellr4.org/wp-content/uploads/sites/2/2020/07/e2835-Editorial-–-COVID-19-pandemic-is-it-time-to-learn-about-DPP-4CD26.pdf |
Similar Items
-
DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01) -
Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01) -
Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01) -
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
by: Alba Sebastián-Martín, et al.
Published: (2022-08-01) -
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)